FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224950024> ?p ?o ?g. }

• W4224950024 endingPage "3189" @default.
• W4224950024 startingPage "3180" @default.
• W4224950024 abstract "To evaluate the clinical benefit of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy (SBRT) in patients with refractory metastatic pancreatic cancer (mPC).Between November 2016 and December 2019, patients with refractory mPC were randomly assigned 1:1 to SBRT of 15 Gy with nivolumab or nivolumab/ipilimumab stratified by performance status (ClinicalTrials.gov identifier: NCT02866383). The primary end point was the clinical benefit rate (CBR), defined as the percentage of patients with complete or partial response (PR) or stable disease, according to RECIST 1.1. Simon's 2-stage phase II optimal design was used independently for both arms, with CBR determining expansion to the second stage. Secondary end points included safety, response rate, duration of response, progression-free survival, and overall survival. Exploratory analyses included biomarkers related to the benefits.Eighty-four patients (41 SBRT/nivolumab and 43 SBRT/nivolumab/ipilimumab) received at least one dose of study treatment. CBR was 17.1% (8.0 to 30.6) for patients receiving SBRT/nivolumab and 37.2% (24.0 to 52.1) for SBRT/nivolumab/ipilimumab. PR was observed in one patient receiving SBRT/nivolumab and lasted for 4.6 months. Six patients receiving SBRT/nivolumab/ipilimumab achieved a PR with a median duration of response of 5.4 months (4.2 to not reached). Grade 3 or higher treatment-related adverse events occurred in 10 (24.4%) and 13 (30.2%) patients in the SBRT/nivolumab and SBRT/nivolumab/ipilimumab groups, respectively. Programmed cell death ligand-1 expression by tumor proportion score or combined positivity score of ≥ 1% was not associated with clinical benefits. On-treatment decreased serum interleukin-6, interleukin-8, and C-reactive protein levels were associated with better overall survival.Clinically meaningful antitumor activity and favorable safety profiles were demonstrated after treatment with SBRT/nivolumab/ipilimumab in patients with refractory mPC. However, the contribution from SBRT is unknown. Further studies are warranted." @default.
• W4224950024 created "2022-04-28" @default.
• W4224950024 creator A5000216165 @default.
• W4224950024 creator A5004947197 @default.
• W4224950024 creator A5009447909 @default.
• W4224950024 creator A5011408952 @default.
• W4224950024 creator A5013434558 @default.
• W4224950024 creator A5024450758 @default.
• W4224950024 creator A5045701610 @default.
• W4224950024 creator A5051043977 @default.
• W4224950024 creator A5054577726 @default.
• W4224950024 creator A5063670944 @default.
• W4224950024 creator A5071040943 @default.
• W4224950024 creator A5071985590 @default.
• W4224950024 creator A5073407255 @default.
• W4224950024 creator A5074122105 @default.
• W4224950024 creator A5077964875 @default.
• W4224950024 creator A5080260090 @default.
• W4224950024 creator A5090876784 @default.
• W4224950024 creator A5091362338 @default.
• W4224950024 date "2022-09-20" @default.
• W4224950024 modified "2023-10-17" @default.
• W4224950024 title "Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)" @default.
• W4224950024 cites W1970415573 @default.
• W4224950024 cites W2019607817 @default.
• W4224950024 cites W2032166347 @default.
• W4224950024 cites W2044363258 @default.
• W4224950024 cites W2049078823 @default.
• W4224950024 cites W2101653483 @default.
• W4224950024 cites W2151253787 @default.
• W4224950024 cites W2156714215 @default.
• W4224950024 cites W2165480504 @default.
• W4224950024 cites W2187917981 @default.
• W4224950024 cites W2254907138 @default.
• W4224950024 cites W2285093314 @default.
• W4224950024 cites W2560628113 @default.
• W4224950024 cites W2578888194 @default.
• W4224950024 cites W2622499649 @default.
• W4224950024 cites W2749989634 @default.
• W4224950024 cites W2787553571 @default.
• W4224950024 cites W2791483720 @default.
• W4224950024 cites W2816152715 @default.
• W4224950024 cites W2913728083 @default.
• W4224950024 cites W2931438826 @default.
• W4224950024 cites W2943074432 @default.
• W4224950024 cites W2956407134 @default.
• W4224950024 cites W2959096163 @default.
• W4224950024 cites W2984359187 @default.
• W4224950024 cites W3004059930 @default.
• W4224950024 cites W3022826062 @default.
• W4224950024 cites W3038009775 @default.
• W4224950024 cites W3080889076 @default.
• W4224950024 cites W3088909433 @default.
• W4224950024 cites W3090467623 @default.
• W4224950024 cites W3119005666 @default.
• W4224950024 cites W3119086885 @default.
• W4224950024 cites W3128131226 @default.
• W4224950024 cites W3163414580 @default.
• W4224950024 cites W3214048256 @default.
• W4224950024 doi "https://doi.org/10.1200/jco.21.02511" @default.
• W4224950024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35476508" @default.
• W4224950024 hasPublicationYear "2022" @default.
• W4224950024 type Work @default.
• W4224950024 citedByCount "18" @default.
• W4224950024 countsByYear W42249500242022 @default.
• W4224950024 countsByYear W42249500242023 @default.
• W4224950024 crossrefType "journal-article" @default.
• W4224950024 hasAuthorship W4224950024A5000216165 @default.
• W4224950024 hasAuthorship W4224950024A5004947197 @default.
• W4224950024 hasAuthorship W4224950024A5009447909 @default.
• W4224950024 hasAuthorship W4224950024A5011408952 @default.
• W4224950024 hasAuthorship W4224950024A5013434558 @default.
• W4224950024 hasAuthorship W4224950024A5024450758 @default.
• W4224950024 hasAuthorship W4224950024A5045701610 @default.
• W4224950024 hasAuthorship W4224950024A5051043977 @default.
• W4224950024 hasAuthorship W4224950024A5054577726 @default.
• W4224950024 hasAuthorship W4224950024A5063670944 @default.
• W4224950024 hasAuthorship W4224950024A5071040943 @default.
• W4224950024 hasAuthorship W4224950024A5071985590 @default.
• W4224950024 hasAuthorship W4224950024A5073407255 @default.
• W4224950024 hasAuthorship W4224950024A5074122105 @default.
• W4224950024 hasAuthorship W4224950024A5077964875 @default.
• W4224950024 hasAuthorship W4224950024A5080260090 @default.
• W4224950024 hasAuthorship W4224950024A5090876784 @default.
• W4224950024 hasAuthorship W4224950024A5091362338 @default.
• W4224950024 hasConcept C121332964 @default.
• W4224950024 hasConcept C121608353 @default.
• W4224950024 hasConcept C126322002 @default.
• W4224950024 hasConcept C141071460 @default.
• W4224950024 hasConcept C142424586 @default.
• W4224950024 hasConcept C143998085 @default.
• W4224950024 hasConcept C197934379 @default.
• W4224950024 hasConcept C203092338 @default.
• W4224950024 hasConcept C2776694085 @default.
• W4224950024 hasConcept C2777701055 @default.
• W4224950024 hasConcept C2778822529 @default.
• W4224950024 hasConcept C2779984678 @default.
• W4224950024 hasConcept C2780030458 @default.

• next